NASDAQ
31.24USD
+1.23 (+4.10%)
We have scored 12 news catalysts on Cogent Biosciences, Inc. (COGT) over the past 12 months. The biggest single-day move next to one of them came Mar 21, 2026, when COGT closed −3.6%: “This $116 Million Buy Joins a 360% Stock Run and Seemingly Signals Conviction in a Key Drug Launch”. Coverage across the window leans positive (average ticker sentiment +0.77). Most of the impact sits in sector healthcare and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
5.4B
P/E
—
EPS
—
Beta
0.31
52W range
13.78-43.73
Day range
30.05–31.50
Open
30.23
Prev close
30.01
Volume
2.3M
Avg volume
2.3M
Dividend
0.00
IPO
2018-03-29
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Cogent Biosciences, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for COGT: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
